Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0000486

Ketorolac trometamol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Ketorolac tris salt, (±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid tris salt, Toradol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H13NO3 · C4H11NO3
CAS Number:
74103-07-4
Molecular Weight:
376.40
MDL number:
MFCD00887595
UNSPSC Code:
41116107
PubChem Substance ID:
329830978
NACRES:
NA.24
Pricing and availability is not currently available.

grade

pharmaceutical primary standard

API family

ketorolac

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(CO)(CO)CO.OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3

InChI

1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2

InChI key

BWHLPLXXIDYSNW-UHFFFAOYSA-N

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ketorolac trometamol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000626

Ketorolac trometamol for peak identification, European Pharmacopoeia (EP) Reference Standard

1356665

Ketorolac Tromethamine, United States Pharmacopeia (USP) Reference Standard

1356326

Ketorolac Related Compound B, United States Pharmacopeia (USP) Reference Standard

1356315

Ketorolac Related Compound A, United States Pharmacopeia (USP) Reference Standard

1356337

Ketorolac Related Compound C, United States Pharmacopeia (USP) Reference Standard

1356348

Ketorolac Related Compound D, United States Pharmacopeia (USP) Reference Standard

PHR2493

Ketorolac Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2494

Ketorolac Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301,H315,H319,H335

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Meizi Wang et al.
Retina (Philadelphia, Pa.), 32(10), 2158-2164 (2012-10-27)
To investigate the concentrations and pharmacokinetics of ketorolac in the rabbits by three different routes of administrations: a single intracameral, intravitreal, and suprachoroidal injection. Fifty-four New Zealand white rabbits received ketorolac (250 μg/0.05 mL) in one eye by a single
David R Drover et al.
Anesthesia and analgesia, 114(6), 1270-1276 (2012-04-03)
Ketorolac tromethamine (ketorolac) administration reduces postoperative opioid requirements. The pharmacokinetic characteristics of intranasal ketorolac tromethamine in children have not been characterized. Our objective of this study was to determine the pharmacokinetics of a single intranasal dose of ketorolac in adolescent
Andy He et al.
Current medical research and opinion, 28(12), 1873-1880 (2012-10-27)
An intranasal (IN) formulation of ketorolac was recently FDA approved in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The aim of this paper is to provide an overview
Hue Jung Park et al.
Anesthesia and analgesia, 116(1), 224-231 (2012-12-12)
Painful neuropathy is a dose-limiting side effect in cancer chemotherapy. To characterize this phenomenon, we examined pain behavior and analgesic actions in a mouse model of cisplatin polyneuropathy. Male C57BL/6 mice received intraperitoneal cisplatin or saline (2.3 mg/kg/d) every other
Henry D Perry et al.
Expert opinion on pharmacotherapy, 7(1), 99-107 (2005-12-24)
Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service